Please login to the form below

Not currently logged in
Email:
Password:

Common ICU drug blocks cardiovascular effects of cocaine

An intensive care unit drug commonly used as a sedative may have the ability to counteract the effects of cocaine on the human cardiovascular system, according to a US study

An intensive care unit drug commonly used as a sedative may have the ability to counteract the effects of cocaine on the human cardiovascular system, according to a US study.

Doctors at UT Southwestern Medical Center published details of their discovery in the 14 August issue of the Journal of the American College of Cardiology.

Precedex (dexmedetomidine), which is manufactured by US-based Orion, was found to lower the heart rate and blood pressure in a clinical trial involving 22 volunteers who had taken a small dose of the drug. Researchers also found that the drug reduced sympathetic nerve activity in the subjects who had taken cocaine.

Dr Wanpen Vongpatanasin, the study's senior author, said: "We have found that cocaine's effects on the cardiovascular system can be reversed by dexmedetomidine, which is currently approved by the FDA for anaesthetic purposes in operating rooms or intensive care units."

The new treatment would prove superior to the current regimen of nitroglycerin, sedatives and blood pressure medications used to treat cocaine-induced medical disorders, because dexmedetomidine also reverses cocaine's adverse effects on heart rate, blood pressure and vascular resistance.

The study authors said further research was needed to see if dexmedetomidine could be used to treat acute cocaine overdose in accident and emergency units.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics